Compare Novartis AG (NVS) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Direxion Daily Semiconductor Bull 3X Shares trades at $139.8 (market cap $24.42B). The key difference: Novartis AG is far larger — about 11× Direxion Daily Semiconductor Bull 3X Shares's market cap, and Novartis AG pays a 3.31% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Direxion Daily Semiconductor Bull 3X Shares for 15 Days on average.
| NVS | SOXL | |
|---|---|---|
Market Cap | $268.57B | $24.42B |
Volume | 1,532,573 | 100,232,380 |
Sector | Health | Leveraged / Inverse |
52-Week High | $168.62 | $300.77 |
52-Week Low | $121.80 | $30.81 |
Typical Hold Time | 82 Days | 15 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, is trading at $139.76, down 12.05% with a bearish technical signal. The fund faces volatility from its 3x leverage on semiconductor stocks, which have shown mixed performance amid strong AI demand but regulatory and market risks. Recent news highlights sector rebounds and institutional selling, while technical indicators show neutral oscillators and key support at $134.
Outlook is cautious due to leverage amplifying sector swings; opportunities exist if semiconductor fundamentals hold, but risks include tariff concerns and overcrowded trades. Investors should weigh high volatility against AI-driven growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
